home / stock / imra / imra news

IMRA News and Press, IMARA Inc. From 04/18/22

Stock Information
Company Name: IMARA Inc.
Stock Symbol: IMRA
Market: NASDAQ
Menu
IMRA IMRA Quote IMRA Short IMRA News IMRA Articles IMRA Message Board
Get IMRA Alerts

News, Short Squeeze, Breakout and More Instantly...
IMRA - NAT, OCX and ENSV among pre market gainers

Casa Systems (CASA) +41% as Verizon buys 9.9% stake. Natus Medical (NTUS) +28% to be acquired by Archimed Group for $33.50/share in cash or $1.2B. MedAvail Holdings (MDVL) +14%. IMARA (IMRA) +11%. Ocugen (OCGN) +7% on commercialization rights for COVID vaccine Co...
IMRA - Tilray, Clever Leaves top healthcare gainers; Celsion, IMARA lead losers' pack

Gainers: Tilray Brands (TLRY) +15%. Clever Leaves (CLVR) +12%. Ensysce Biosciences (ENSC) +11%. Icosavax (ICVX) +10%. Cullinan Oncology (CGEM) +6%. Losers: Celsion (CLSN) -19%. IMARA (IMRA) -14%. Owlet (OWLT) -12%. PAVmed (PAVM) -10%. Accelerate Diagnos...

IMRA - IMTE, MF and SABS among mid-day movers

Gainers: Sunshine Biopharma (SBFM) +132%. Dingdong Limited (DDL) +29%. System1 (SST) +27%. FG Financial Group (FGF) +25%. Missfresh (MF) +21%. BT Brands (BTBD) +20%. Longeveron (LGVN) +18%. Compass Therapeutics (CMPX) +18%. Allego (ALLG) +17%. Nam Tai Property (NTP) +15%. Losers: IMARA (IMRA)...

IMRA - Sunshine Biopharma, Nano-X top healthcare gainers; IMARA, GBS lead losers' pack

Gainers: Sunshine Biopharma (SBFM) +181%. Nano-X Imaging (NNOX) +15%. Arcus Biosciences (RCUS) +13%. Cue Biopharma (CUE) +11%. Dermata Therapeutics (DRMA) +6%. Losers: IMARA (IMRA) -35%. GBS (GBS) -15%. Precipio (PRPO) -13%. Cassava Sciences (SAVA) -10%...
IMRA - Cognyte Software, Vertex Energy, Red Cat Holdings among premarket losers' pack

IMARA (IMRA) -40% as it plans to cull sickle cell/beta-thalassemia programs of tovinontrine after 2 trials disappoint. Cognyte Software (CGNT) -24% on Q4 earnings release GBS (GBS) -16%. Acer Therapeutics (ACER) -10%. Takung Art (TKAT) -8%. Precipio PRPO -7% on F...

IMRA - Imara slumps 39% as it plans to cull sickle cell/beta-thalassemia programs of tovinontrine after 2 trials disappoint

Imara (NASDAQ:IMRA) said it will discontinue further development of tovinontrine (IMR-687) in sickle cell disease (SCD) and beta-thalassemia after the therapy failed to show benefit in two phase 2b trials. The Boston-based company is also discontinuing the two phase 2b studies ...

IMRA - Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat population Interim results in Forte trial for beta-thalassemia demonstrated no mean...
IMRA - Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript

Imara Inc. (IMRA) Q4 2021 Earnings Conference Call March 15, 2022 8:30 am ET Company Participants Rahul Ballal - President, Chief Executive Officer Mike Gray - Chief Financial Officer, Chief Operating Officer Ken Attie - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - C...

IMRA - Imara GAAP EPS of -$2.37 beats by $0.21

Imara press release (NASDAQ:IMRA): FY GAAP EPS of -$2.37 beats by $0.21. Cash, cash equivalents and investments of $90.28M. CEO comment: "We are pleased to have expanded our pipeline with the addition of IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2–related fac...

IMRA - Imara Reports Full Year 2021 Financial Results and Business Highlights

Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary endpoint of Ardent Phase 2b trial in sickle cell disease to reductions in annualized r...
Previous 10 Next 10